Eskreis-Winkler Sarah, Simon Katherine, Reichman Melissa, Spincemaille Pascal, Nguyen Thanh D, Christos Paul J, Drotman Michele, Prince Martin R, Pinker Katja, Sutton Elizabeth J, Morris Elizabeth A, Wang Yi
Department of Radiology, Weill Cornell Medicine, New York, NY, United States.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Front Oncol. 2021 Mar 22;11:605014. doi: 10.3389/fonc.2021.605014. eCollection 2021.
To assess the feasibility and diagnostic accuracy of multispectral MRI (MSI) in the detection and localization of biopsy markers during MRI-guided breast biopsy.
This prospective study included 20 patients undergoing MR-guided breast biopsy. In 10 patients (Group 1), MSI was acquired following tissue sampling and biopsy marker deployment. In the other 10 patients (Group 2), MSI was acquired following tissue sampling but before biopsy marker deployment (to simulate deployment failure). All patients received post-procedure mammograms. Group 1 and Group 2 designations, in combination with the post-procedure mammogram, served as the reference standard. The diagnostic performance of MSI for biopsy marker identification was independently evaluated by two readers using two-spectral-bin MR and one-spectral-bin MR. The κ statistic was used to assess inter-rater agreement for biopsy marker identification.
The sensitivity, specificity, and accuracy of biopsy marker detection for readers 1 and 2 using 2-bin MSI were 90.0% (9/10) and 90.0% (9/10), 100.0% (10/10) and 100.0% (10/10), 95.0% (19/20) and 95.0% (19/20); and using 1-bin MSI were 70.0% (7/10) and 80.0% (8/10), 100.0% (8/8) and 100.0% (10/10), 85.0% (17/20) and 90.0% (18/20). Positive predictive value was 100% for both readers for all numbers of bins. Inter-rater agreement was excellent: κ was 1.0 for 2-bin MSI and 0.81 for 1-bin MSI.
MSI is a feasible, diagnostically accurate technique for identifying metallic biopsy markers during MRI-guided breast biopsy and may eliminate the need for a post-procedure mammogram.
评估多光谱磁共振成像(MSI)在磁共振成像引导下乳腺活检过程中检测活检标记物及定位的可行性和诊断准确性。
这项前瞻性研究纳入了20例行磁共振成像引导下乳腺活检的患者。10例患者(第1组)在组织取样和放置活检标记物后进行多光谱磁共振成像。另外10例患者(第2组)在组织取样后但在放置活检标记物前进行多光谱磁共振成像(以模拟放置失败)。所有患者均接受术后乳房X线摄影。第1组和第2组的分组情况,结合术后乳房X线摄影,作为参考标准。由两名阅片者使用双光谱区磁共振成像和单光谱区磁共振成像独立评估多光谱磁共振成像对活检标记物识别的诊断性能。采用κ统计量评估活检标记物识别的阅片者间一致性。
阅片者1和阅片者2使用双光谱区多光谱磁共振成像检测活检标记物的灵敏度、特异度和准确度分别为90.0%(9/10)和90.0%(9/10)、100.0%(10/10)和100.0%(10/10)、95.0%(19/20)和95.0%(19/20);使用单光谱区多光谱磁共振成像时分别为70.0%(7/10)和80.0%(8/10)、100.0%(8/8)和100.0%(10/10)、85.0%(17/20)和90.0%(18/20)。所有光谱区的阳性预测值对两位阅片者均为100%。阅片者间一致性良好:双光谱区多光谱磁共振成像的κ值为1.0,单光谱区多光谱磁共振成像的κ值为0.81。
多光谱磁共振成像是一种可行的、诊断准确的技术,可用于在磁共振成像引导下乳腺活检过程中识别金属活检标记物,且可能无需术后乳房X线摄影。